血脂康与他汀类药物调脂效果对比及安全性分析

Comparison of effectiveness and safety between Xuezhikang and statins for hyperlipidemia

目的评价血脂康与常见他汀类降脂药物对原发性高脂血症疗效。方法计算机检索Pub Med、Cochrane图书馆、万方医学数据库、维普中文科技期刊全文数据库,筛选关于中药血脂康与他汀类药物治疗原发性高脂血症随机对照实验。评价指标包括胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)。采用Revman5.3软件进行分析。结果实验共纳入14篇文献,共计1150例患者,结果血脂康、他汀类药物均明显降低原发性高脂血症患者TC、TG、LDL-C,明显升高HDL-C,但Meta分析提示血脂康与他汀类药物对原发性高脂血症患者降低血TC、TG、LDL-C疗效差异无统计学意义[WMD=0.01mmol/L,95%CI:(-0.05~0.07)mmol/L,P>0.05;WMD=0.07 mmol/L,95%CI:(-0.26~0.41)mmol/L,P>0.05;WMD=0.13 mmol/L,95%CI:(-0.44~0.69)mmol/L,P>0.05],对升高患者血高密度脂蛋白疗效差异无统计学意义[WMD=0.13 mmol/L,95%CI:(-0.44~0.69)mmol/L,P>0.05]。结论血脂康与他汀类药物均可降低原发性高脂血症患者血TC、TG、LDL-C,升高血HDL-C,两者疗效相当,血脂康致不良反应更少,安全性更高。

Objective To review systematically the effectiveness and safety of Xuezhikang and Statins for the patients with primary hyperlipidemia. Methods A literature research was performed in Cochrane library, PubMed, CNKI, WANFANG DATA and VIP full-text database to collect randomized controlled trials（RCT） about effectiveness of Xuezhikang and Statins for the patients with primary hyperlipidemia published from 1st June 2010 to 1st June 2015. The efficacy evaluation and safety were reviewed and a Meta-analysis was performed By using Revman 5.3 software. Results 1150 patients from 14 independent trials were included in this review. There were no homogeneity among most of the studies （P 〈 0.05, I^2 〉 0.75 ） , and the level of TC ,TG,LDL-C in both Xuezhikang group and Statins group was lowered significantly,while the HDL-C level was elevated significantly. The results of Meta-analysis showed that there were no difference in the level of TC,TG, LDL-C and HDL-C between the two groups [ WMD = 0. 01mmol/L, 95% CI： （ - 0.05 - 0. 07 ） mmol/L,P 〉 0. 05 ; WMD = 0.07mmol/L,95 % CI： （ - 0. 26 -0. 41 ） mmol/L, P 〉 0.05 ; WMD = 0. 13 mmol/L ,95% CI： （ - 0. 44 - 0. 69 ） mmol/L ,P 〉 0.05 ; WMD = 0.13mmol/L ,95% CI： （ - 0. 44 -0. 69 ） mmol/L, P 〉 0.05 ]. Conclusion Both Xuezhikang and Statins show the effectiveness for the patients with primary hyperlipidemia, but Xuezhikang with less adverse events.